Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Rating of “Hold” by Brokerages

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have been assigned an average rating of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $5.5125.

Several equities analysts have issued reports on CHRS shares. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer started coverage on shares of Coherus Oncology in a report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price target for the company.

Coherus Oncology Trading Down 4.7%

NASDAQ:CHRS opened at $1.63 on Monday. Coherus Oncology has a 12-month low of $0.71 and a 12-month high of $2.62. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42. The stock’s 50 day simple moving average is $1.70 and its 200-day simple moving average is $1.49. The firm has a market cap of $243.64 million, a P/E ratio of 1.23 and a beta of 0.99.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CHRS. Acadian Asset Management LLC raised its position in Coherus Oncology by 52,980.1% in the first quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 196,556 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Coherus Oncology during the 2nd quarter worth $33,000. Geode Capital Management LLC grew its stake in shares of Coherus Oncology by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,676,476 shares of the biotechnology company’s stock worth $1,958,000 after purchasing an additional 20,976 shares during the period. XTX Topco Ltd increased its holdings in shares of Coherus Oncology by 65.3% in the 2nd quarter. XTX Topco Ltd now owns 91,739 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 36,257 shares in the last quarter. Finally, Tejara Capital Ltd increased its holdings in shares of Coherus Oncology by 1.7% in the 2nd quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock valued at $511,000 after purchasing an additional 11,552 shares in the last quarter. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.